News
Archive: May 2025
Interim results for six months ending 31 March 2025
20 May 2025 IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announces its unaudited interim results for the six months ended 31 March 2025 (‘H1 2025’ or the ‘period’). Financial highlights Revenues up 26% to £3.